A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Clinical trial NCT06136650 · RECRUITING

Trial details

NCT number: NCT06136650
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms

Start date: 2023-12-18
Primary completion: 2028-05-10
Enrollment: 1314

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.